Note 1: Segment Information continued Segment information has been adjusted to exclude amortisation and impairment of acquired intellectual property (IP) and significant non-recurring items including one-off impairments and restructuring costs, business acquisitions and disposals. Underlying NPATA represents the statutory net (loss)/profit after tax before amortisation of acquired IP and significant nonrecurring items including those related to one-off restructuring and impairments expenses, business acquisitions and disposals. The following table presents a reconciliation between the segment information and statutory results, reported on an underlying basis, along with the following page that further reconciles key line items to the Group’s statutory results. CSL Behring CSL Vifor CSL Seqirus Consolidated Entity US$m 2026 2025 2026 2025 2026 2025 2026 2025 Sales and service revenue 11,087 10,930 2,316 2,199 1,809 1,906 15,212 15,035 Influenza pandemic facility reservation fees — — — — 183 179 183 179 Royalties and license revenue 263 190 40 26 — — 303 216 Other income 37 38 23 9 39 81 99 128 Total segment revenue 11,387 11,158 2,379 2,234 2,031 2,166 15,797 15,558 Segment gross profit 5,648 5,641 1,655 1,545 1,151 1,257 8,454 8,443 Segment gross profit % 49.6% 50.6% 69.6% 69.2 % 56.7% 58.0% 53.5% 54.3% Selling and marketing expenses (1,036) (937) (403) (449) (252) (230) (1,691) (1,616) Segment operating result 4,612 4,704 1,252 1,096 899 1,027 6,763 6,827 Segment operating result % 40.5% 42.2% 52.6% 49.1 % 44.3% 47.4% 42.8% 43.9% Research and development expenses (1,223) (1,359) General and administrative expenses (920) (1,000) Underlying EBIT 4,620 4,468 Finance costs (435) (448) Finance income 30 38 Underlying profit before tax 4,215 4,058 Income tax expense (879) (645) Underlying NPATA 3,336 3,413 - Attributable to CSL Limited shareholders 3,098 3,219 - Attributable to non-controlling interests 238 194 Underlying EBIT 4,620 4,468 Restructuring and impairment expenses (7,923) — Net gain on business disposals — 30 Amortisation of other intangibles (excluding acquired IP)1 9 5 7 7 17 20 107 104 Depreciation1 352 335 24 23 74 59 555 549 Impairment — — — — — — 7,079 — EBITDA2 4,973 5,044 1,283 1,126 990 1,106 4,438 5,151 95 Notes to the Financial Statements 1 Depreciation and amortisation (excluding IP) of $179m (2025: $204m) relate to non-segment expenditure and are not allocated to segments. 2 The Group's EBITDA of $4,438m (2025: $5,151m) represents statutory operating (loss)/profit (EBIT) of ($3,682m) (2025: $4,134m) as reported in the consolidated income statement adding back total depreciation and amortisation expense of $1,041m (2025: $1,017m) and impairment of $7,079m outlined in Note 2 and 3 respectively. The Group's EBITDA includes $2,808m (2025: $2,125m) of costs that are not allocated to segments. The costs are primarily attributable to centralised activities being R&D and general and administration along with restructuring activities (excluding impairment) (Note 3). 95 CSL Limited Annual Report 2025/26
RkJQdWJsaXNoZXIy MjE2NDg3